PMID- 23091809
OWN - NLM
STAT- MEDLINE
DCOM- 20130319
LR  - 20211021
IS  - 2287-285X (Electronic)
IS  - 2287-2728 (Print)
IS  - 2287-2728 (Linking)
VI  - 18
IP  - 3
DP  - 2012 Sep
TI  - Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, 
      cirrhosis and hepatocellular carcinoma.
PG  - 287-94
LID - 10.3350/cmh.2012.18.3.287 [doi]
AB  - BACKGROUND/AIMS: Cyclooxygenase-2 (COX-2) and vascular endothelial growth factor 
      (VEGF) are up-regulated in hepatocellular carcinoma (HCC). To investigate the 
      levels of COX-2 and VEGF expression in chronic hepatitis (CH), cirrhosis, and 
      HCC. METHODS: The immunohistochemical expressions of COX-2 and VEGF were 
      evaluated in tissues from patients with CH (n=95), cirrhosis (n=38), low-grade 
      HCC (LG-HCC; n=6), and high-grade HCC (HG-HCC; n=29). RESULTS: The COX-2 
      expression scores in CH, cirrhosis, LG-HCC, and HG-HCC were 3.3+/-1.9 (mean+/-SD), 
      4.2+/-1.7, 5.5+/-1.0, and 3.4+/-2.4, respectively (CH vs. cirrhosis, P=0.016; CH vs. 
      LG-HCC, P=0.008; LG-HCC vs. HG-HCC, P=0.004), and the corresponding VEGF 
      expression scores were 0.9+/-0.8, 1.5+/-0.7, 1.8+/-0.9, and 1.6+/-1.1 (CH vs. cirrhosis, 
      P<0.001; CH vs. LG-HCC, P=0.011; LG-HCC vs. HG-HCC, P=0.075). Both factors were 
      correlated with the fibrosis stage in CH and cirrhosis (COX-2: r=0.427, P<0.001; 
      VEGF: r=0.491, P<0.001). There was a significant correlation between COX-2 and 
      VEGF in all of the tissue samples (r=0.648, P<0.001), and between high COX-2 and 
      VEGF expression scores and survival (COX-2: P=0.001; VEGF: P<0.001). CONCLUSIONS: 
      The expressions of both COX-2 and VEGF are significantly higher in cirrhosis and 
      LG-HCC than in CH. High COX-2 and high VEGF expressions are associated with a 
      high survival rate.
FAU - Kwon, Soon Ha
AU  - Kwon SH
AD  - Division of Gastroenterology, Department of Internal Medicine, Soonchunhyang 
      University College of Medicine, Seoul, Korea.
FAU - Jeong, Soung Won
AU  - Jeong SW
FAU - Jang, Jae Young
AU  - Jang JY
FAU - Lee, Ji Eun
AU  - Lee JE
FAU - Lee, Sae Hwan
AU  - Lee SH
FAU - Kim, Sang Gyune
AU  - Kim SG
FAU - Kim, Young Seok
AU  - Kim YS
FAU - Cho, Young Deok
AU  - Cho YD
FAU - Kim, Hong Soo
AU  - Kim HS
FAU - Kim, Boo Sung
AU  - Kim BS
FAU - Jin, So-Young
AU  - Jin SY
LA  - eng
PT  - Journal Article
DEP - 20120925
PL  - Korea (South)
TA  - Clin Mol Hepatol
JT  - Clinical and molecular hepatology
JID - 101586730
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Hepatocellular/*metabolism/mortality/pathology
MH  - Cyclooxygenase 2/*metabolism
MH  - Female
MH  - Hepatitis, Chronic/*metabolism/mortality/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Liver Cirrhosis/*metabolism/mortality/pathology
MH  - Liver Neoplasms/*metabolism/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Vascular Endothelial Growth Factor A/*metabolism
PMC - PMC3467432
OTO - NOTNLM
OT  - Chronic hepatitis
OT  - Cyclooxygenase-2
OT  - Hepatocellular carcinoma
OT  - Liver cirrhosis
OT  - Vascular endothelial growth factor
COIS- The authors have no conflicts to disclose.
EDAT- 2012/10/24 06:00
MHDA- 2013/03/21 06:00
PMCR- 2012/09/01
CRDT- 2012/10/24 06:00
PHST- 2012/07/09 00:00 [received]
PHST- 2012/08/06 00:00 [revised]
PHST- 2012/08/09 00:00 [accepted]
PHST- 2012/10/24 06:00 [entrez]
PHST- 2012/10/24 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
PHST- 2012/09/01 00:00 [pmc-release]
AID - 10.3350/cmh.2012.18.3.287 [doi]
PST - ppublish
SO  - Clin Mol Hepatol. 2012 Sep;18(3):287-94. doi: 10.3350/cmh.2012.18.3.287. Epub 
      2012 Sep 25.